Good news | The national “Science and Technology Innovation 2030 Major Project” jointly applied for by Zhejiang University, Wuxi People’s Hospital, AlloDx and others was officially launched
Recently, the National Science and Technology Innovation 2030 - "Research on the Prevention and Treatment of Cancer, Cardio-Cerebrovascular, Respiratory and Metabolic Diseases" major project (hereinafter referred to as the "Science and Technology Innovation 2030 Major Project") - "Ultra-high-precision nucleic acid sequencing in lung transplant rejection monitoring", which was commissioned by the National Health Commission, led by Zhejiang University, and Wuxi People's Hospital, AlloDx and others, was applied as a joint unit.
Recently, the major national S&T Innovation 2030 project—'Research on Prevention and Treatment of Cancer, Cardiovascular and Cerebrovascular, Respiratory, and Metabolic Diseases'—entitled 'Application Strategy Research of Ultra-High-Accuracy Nucleic Acid Sequencing in Lung Transplant Rejection Monitoring,' commissioned by the National Health Commission and led by Zhejiang University with Wuxi People's Hospital and AlloDx as co-applicants, was officially launched. As the testing service undertaking unit of this project, AlloDx will undertake the donor-derived cfDNA (dd-cfDNA) testing and data analysis work under the project.
AlloDx's approval of this major R&D special project reflects experts' recognition of the company's strength and experience in the organ-transplant dd-cfDNA testing application field. AlloDx is among the early Chinese companies to successfully develop dd-cfDNA testing technology and has accumulated considerable experience in dd-cfDNA testing throughput, turnaround time, and sample database scale. Based on a lung-transplant dd-cfDNA testing platform, the company has completed screening of lung-specific nucleosome SNPs/Indels, high-order capture probe library design, sequencing depth uniformity, stability, and test background noise-reduction experiments. Leveraging its next-generation sequencing (NGS) high-throughput platform and multiple self-developed core technologies, AlloDx has cumulatively completed testing of over 15,000 dd-cfDNA samples.
Science and Technology Innovation 2030 Major ProjectsMajor projects are major science and technology projects and major projects that reflect the national strategic intentions with 2030 as the time node. They are a group of major scientific and technological innovation projects that are closely related to the long-term development of the national strategy and people's lives and are deployed by our country for 2030 in accordance with the "National Innovation-Driven Development Strategy Outline" and the national "13th Five-Year Plan" outline. Among them, The "Research on the Prevention and Treatment of Cancer, Cardio-Cerebrovascular, Respiratory and Metabolic Diseases" major special project focuses on the cutting-edge science and technology for the prevention and treatment of chronic diseases. It aims to focus on superior forces to carry out scientific research, promote the output of original new technologies, new products, new programs and new strategies for disease prevention and treatment, and strengthen the supporting role of scientific research in the prevention and treatment of major chronic diseases and the strategic goals of Healthy China.
AllDx
AlloDx (AlloDx) was founded in 2018. It focuses on the research and development of new generation molecular diagnostic technologies and clinical transformation in the field of transplantation. It is a national high-tech enterprise and a science and technology small and medium-sized enterprise of the Ministry of Science and Technology. It has received honors such as Shanghai's 2021 Science and Technology Small and Medium Enterprises Innovation Fund Support and the Ministry of Science and Technology's Science and Technology Innovation 2030-"Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory and Metabolic Diseases" major projects.
AlloDx is among the early companies in China with dd-cfDNA application technology for organ transplantation. Based on its omics testing platform, bioinformatics analysis platform, and data deep-learning platform, the company has successfully developed products and services including genetic testing for hereditary kidney disease, non-invasive post-transplant rejection testing, differential testing for polyomavirus-associated nephropathy, pathogen infection screening, and transplant-related antibody testing. It holds 18 core invention patents and 23 software copyrights, has cooperatively published 20 papers on donor cell-free DNA (of which 15 are SCI), and multiple cooperative research results have been invited for presentation at the American Transplant Congress (ATC), European Society for Organ Transplantation (ESOT), and The Transplantation Society (TTS).
The company has established laboratories in Shanghai, Suzhou, and Wuxi for R&D, research-sample, and clinical-sample testing, and holds medical testing laboratory qualifications. The total laboratory area exceeds 2,300 square meters, including immunology, P2, and standard PCR laboratories, and is equipped with next-generation high-throughput sequencers, Luminex, microplate readers, and Q-PCR instruments. It has reached dd-cfDNA technical cooperation with nearly 50 transplant centers in China and completed testing of over 15,000 dd-cfDNA samples, accumulating a substantial 'China Organ Transplant dd-cfDNA Gene Database.'